Different aspects of adherence to antihypertensive treatments

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 3, 2004, Pages 317-333

  Lopatriello, Stefania ^a   Berto, Patrizia ^a   Cramer, Joyce A ^b   Bustacchini, Silvia ^c   Ruffo, Pierfrancesco ^c  

^a Pbe Consulting   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DuPont Italia Srl   (Italy)

Author keywords

Adherence; Antihypertensive medications; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LISINOPRIL; LOSARTAN; NICARDIPINE; NIFEDIPINE; QUINAPRIL; TRANDOLAPRIL;

ANTIHYPERTENSIVE THERAPY; CLINICAL OBSERVATION; CLINICAL TRIAL; EDUCATION; EXPERIMENTAL DESIGN; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; INFORMATION PROCESSING; METHODOLOGY; MOTIVATION; NOMENCLATURE; PATIENT ATTITUDE; PATIENT COMPLIANCE; QUALITATIVE ANALYSIS; RELIABILITY; REVIEW; TREATMENT OUTCOME;

EID: 2942511644     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.3.317     Document Type: Review

References (80)

1. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC VII report. JAMA 289, 2560-2572, (2003).
2. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21, 1011-1053 (2003).
3. Cramer J. Consequences of intermittent treatment for hypertension: the case of medication compliance and persistence. Am. J. Man. Care 4(11), 1563-1568 (1998).
4. Berto P, Lopatriello S. Long-term social costs of hypertension. Expert Rev. Pharmacoeconomics Outcomes Res. 3(1), 33-40 (2003).
5. Paramore LC, Halpern MT, Lapuerta P et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am. J. Manag. Care 7(4), 389-398 (2001).
6. Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo JP. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med. Care 35(11), 11641-1170 (1997).
7. Mallion JM, Baguet JP, Siche JP et al. Compliance, electronic monitoring and antihypertensive drugs. J. Hypertens. 16(Suppl. 1), S75-S80 (1997).
8. Burnier M. Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press. Mon. 5(Suppl. 1), S31-S34 (2000).
9. Cramer J. Medicine partnership. Heart 89(Suppl. II), II19-II21 (2003).
10. Revicki D, Frank L. Pharmacoeconomic evaluation in the real world. PharmacoEconomics 15 (5), 423-434 (1999).
11. Payne K, Esmonde-White S. Observation studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr. Hypertens. Rep. 2, 515-524 (2000).
12. Gerth WC. Compliance and persistence with newer antihypertensive agents. Curr. Hypertens. Rep. 4, 424-433 (2002).
13. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am. J. Hypertens. 10, 697-704 (1997).
14. Feldman R, Bacher M, Campbell N, Drover A, Chockalingam A. Adherence to pharmacologic management of hypertension. Can. J. Public Health 89(5), 16-18 (1998).
15. Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. In: Health Care Cost, Quality and Outcomes. ISPOR Book of Terms. International Society for Pharmacoeconomics and Outcomes Research, 22 (2003).
16. Patel R, Taylor S. Factors affecting medication adherence in hypertensive patients. Ann. Pharmacother. 36, 40-45 (2002).
17. Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Curr. Hypertens. Rep. 2, 510-514 (2000).
18. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch. Intern. Med. 150(7), 1509-1510 (1990).
19. Degli Esposti L, Degli Esposti E, Valpiani G et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin. Ther. 24(8), 1347-1357, discussion 1346 (2002).
20. Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy- the role of adverse effects and compliance. Blood Press. 7, 313-315 (1998).
21. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 160(1), 31-37 (1999).
22. Jokisalo E, Kumpusalo E, Enlund H, Halonen P, Takala J. Factors related to noncompliance with antihypertensive drug therapy. Hum. Hypertens. 16(8), 577-583 (2002).
23. Ren XS, Kazis LE, Lee A, Zhang H, Miller DR. Identifying patient and physician characteristics that affect compliance with antihypertensive medications. J. Clin. Pharm. Ther. 27(1), 47-56 (2002).
24. Iskedjian M, Einarson TR, MacKeigan LD et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy. evidence from a meta-analysis. Clin. Ther. 24(2), 302-316 (2002).
25. Schmieder RE, Rockstroh JK, Gatzka CD, Ruddel H, Schachinger H. Discontinuation of antihypertensive therapy: prevalence of relapses and predictors of successful withdrawal in a hypertensive community. Cardiology 88(3), 277-284 (1997).
26. Choo PW, Rand CS, Inui TS et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med. Care 37(9), 846-857 (1999).
27. Waeber B, Vetter W, Darioli R, Keller U, Brunner HR. Improved blood pressure control by monitoring compliance with antihypertensive therapy. IJCP 53(1), 37-38 (1999).
28. BaileyB, Carney S, Gillies A, McColm L, Smith A, Taylor M. Hypertension treatment compliance: what do patients want to know about their medications? Prog. Cardiovasc. Nurs. 12(4), 23-28 (1997).
29. Kyngas H, Lahdenpera T. Compliance of patients with hypertension and associated factors. J. Adv. Nurs. 29(4), 832-839 (1999).
30. Balazovjech I, Hnilica P Jr. Compliance with antihypertensive treatment in consultation rooms for hypertensive patients. J. Hum. Hypertens. 7(6), 581-583 (1993).
31. Richardson MA, Simons-Morton B, Annegers JF. Effect of perceived barriers on compliance with antihypertensive medication. Health Educ. Q. 20(4), 489-503 (1993).
32. Morrell RW, Park DC, Kidder DP, Martin M. Adherence to antihypertensive medications across the life span. Gerontologist 37(5), 609-619 (1997).
33. Svensson S, Kjellgren KI, Ahlner J, Saljo R. Reasons for adherence with antihypertensive medication. Int. J. Cardiol. 76(2-3), 157-163 (2000).
34. Choo PW, Rand CS, Inui TS, Lee ML, Canning C, Platt R. A cohort study of possible risk factors for over-reporting of antihypertensive adherence. BMC Cardiovasc. Disord. 1 (2001).
35. Lee JY, Kusek JW, Greene PG et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am. J. Hypertens. 9(8), 719-725 (1996).
36. Nuesch R. Schroeder K, Dieterle T, Martina B, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. Br. Med. J. 323, 142-146 (2001).
37. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br. Med. J. 311, 293-295 (1995).
38. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. Compliance with antihypertensive therapy among elderly Medicaid enrolees: the roles of age, gender, and race. Am. J. Public Health 86(12), 1805-1808 (1996).
39. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J. Hum. Hypertens. 12(8), 533-537 (1998).
40. Okano GJ, Rascati K, Wilson J, Remuund D, Grabenstein J, Brixner D. Patterns of antihypertensive use among patients in the US Department of Defence Database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. Clin. Ther. 19(6), 1433-1445 (1997).
41. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin. Ther. 19(6), 1446-1457 (1997).
42. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin. Ther. 20(4), 671-681 (1998).
43. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 160(1), 41-46 (1999).
44. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs Healthcare System Ann. Pharmacother. 36(6), 986-991 (2002).
45. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can. J. Cardiol. 18(6), 649-656 (2002).
46. Degli Esposti E, Sturani A, Di Martino M et al. Long-term persistence with antihypertensive drugs in new patients. J. Hum. Hypertens. 16(6), 439-444 (2002).
47. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J. Hum. Hypertens. 16(8), 569-575 (2002).
48. Burnier M, Scheneider MP, Chiolèro A, et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J. Hypertens. 19(2), 335-341 (2001)
49. Saito I, Saruta T. Effect of education through a periodic newsletter on persistence with antihypertensive therapy. Hypertens. Res. 26(2), 159-162 (2003).
50. Gregoire JP, Moisan J, Guibert R et al. Determinants of discontinuation of new courses of antihypertensive medications. J. Clin. Epidemiol. 55(7), 728-735 (2002).
51. Detry JM. Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Clin. Cardiol. 17(Suppl. III), III12-III16 (1994).
52. Detry JM, Block P, De Backer G, Degaute JP. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. Eur J. Clin. Pharmacol. 47(6), 477-481 (1995).
53. Elliott HL, Elawad M, Wilkinson R, Singh SP. Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system. J. Hypertens. 20(2), 333-338 (2002).
54. Mounier-Vehier C, Bernaud C, Carre A, Lequeuche B, Hotton JM, Charpentier JC. Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. Am. J. Hypertens. 11, 478-486 (1998).
55. Leenen FH, Wilson TW, Bolli P et al. Patterns of compliance with once- versus twice-daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can. J. Cardiol. 13(10), 914-920 (1997).
56. Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P, Carre A. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once-daily- versus twice-daily regimen. Am. J. Hypertens. 13(2), 184-190 (2000).
57. Boissel JP, Meillard O, Perrin-Fayolle E et al. Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect. The EOL Research Group. Eur. J. Clin. Pharmacol. 50(1-2), 63-67 (1996).
58. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag. Care 9(9), S2-S6 (2000).
59. Benson S, Kyle VB, Raddatz J. Time to patient discontinuation of antihypertensive drugs in different classes. Am. J. Health-Syst. Pharm. 57(1), 51-54 (2000).
60. Skaer TL, Sclar DA, Markowski DJ, Won JK. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. J. Hum. Hypertens. 7(5), 515-518 (1993).
61. Friedman RH, Kazis LE, Jette A et al. Telecommunications system for monitoring and counselling patients with hypertension. Impact on medication adherence and blood pressure control. Am J. Hypertens. 9(4 Pt 1), 285-292 (1996).
62. Patton K, Meyers J, Lewis BE. Enhancement of compliance among patients with hypertension. Am. J. Manag. Care 3(11), 1693-1698 (1997).
63. Collins L, Ivey AM. The relationship of patient education and hypertension treatment compliance. J. Am. Acad. Nurse Pract. 11(8), 331-334 (1999).
64. Applegate BW, Ames SC, Mehan DJ Jr, McKnight GT, Jones GN, Brantley PJ. Maximizing medication adherence in low-income hypertensives: a pilot study. J. LA State Med. Soc. 152, 349-356 (2000).
65. Enlund H, Jokisalo E, Wallenius S, Korhonen M. Patient-perceived problems, compliance, and the outcome of hypertension treatment. Pharm. World Sci. 23(2), 60-64 (2001).
66. Cramer, JA, Ouellette, VL, Mattson, RH. The effect of microelectronic observation on compliance. Epilepsia 31, 617-618 (1990).
67. Rudd P. Compliance with antihypertensive therapy: a shifting paradigm. Cardiol. Rev. 25, 230-240 (1994).
68. Park DC. Applied cognitive aging research. In: The Handbook of Aging and Cognition. Craik FIM, Salthouse TA (Eds). Laurence Erlbawn, NJ, USA, 449-493 (1992)
69. Park DC. Self-regulation and control of rheumatic disorders. Int. Rev. Health Psychol. 3, 189-197 (1994).
70. Park DC, Jones TR. Medication adherence and aging. In: Handbook of Human Factors and the Holder Adult. Fish AD, Rogers WA (Eds). Laurence Erlbaum, NJ, USA 369-390 (1996)
71. Janz NK, Becker MH. The health belief model: a decade later. Heath Educ. Q. 11, 1-47 (1984).
72. Sole24OreSAnità. USA: Compliance Nel Mirino. The Boston Consulting Group. 4 (11), 3-9 (2004).
73. Horne R, Clatworthy J, Polmear A, Weinman J. Anglo-Scandinavian Cardiac Outcomes Trial. Do hypertensive patients' beliefs about their illness and treatment influence medication adherence and quality of life? J. Hum. Hypertens. 15 (Suppl. 1), S65-S68 (2001).
74. Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental illness. J. Nerv. Mental Dis. 187, 52-54 (1999).
75. Cramer JA, Rosenheck R. Kirk G, Krol W, Krystal JH and the VA Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 6, 566-573 (2003).
76. Ross SD, Akhras KS, Zhang S, Rozinsky M, Nalysnyk L. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy 21(8), 940-953 (2001).
77. Salas M, In't Veld BA, van der Linden PD, Hofman A, Breteler M, Stricker BH. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin. Pharmacol. Ther. 70(6), 561-566 (2001).
78. Mallion JM, Dutrey-Dupagne C, Vaur L et al. Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild-to-moderate hypertension. J. Hypertens. 14(1), 137-144 (1996).
79. Choo PW, Rand CS, Inui TS, Lee ML, Ma CC, Platt R. A pharmacodynamic assessment of the impact of antihypertensive nonadherence on blood pressure control. Pharmacoepidemiol. Drug Saf. 9(7), 557-563 (2000).
80. Schoberberger R, Janda M, Pescosta W, Sonneck G. The COMpliance Praxis Survey (COMPASS): a multidimensional instrument to monitor compliance for patients on antihypertensive medication. J. Hum. Hypertens. 16(11), 779-787 (2002).